ClinicalTrials.gg
RecruitingNCT06653660TIMOUNPUBERTYUpdated Nov 17, 2025

Exposure to Organochlorine Pollutants and Impact on Development in the Peripubertal Age in Guadeloupe

An observational study in Prenatal Exposure and Postnatal Exposure, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Recruiting at 1 site in Guadeloupe. Open to participants aged 16 Years to 22 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Observational

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
16 Years to 22 Years
Sex
All
01

Study summary

In the context of environmental pollution of the French West Indies by chlordecone and questions about health consequences, monitoring at the peripubertal age of children born alive in the TIMOUN cohort is justified in several respects: - existence of an already established mother-child cohort whose live-born children will reach peripubertal ages during the period 2020-2022; - opportunity to verify hypotheses put forward on the basis of toxicological data acquired in laboratory animals and the hormonal characteristics of chlordecone (endocrine disruptor); - strong societal demand for such research to be carried out because of concerns about the sensitivity of children and adolescents to the effects of environmental xenobiotics, in particular on sexual development and the age of puberty; - recommendation of the Scientific Council Chlordecone Inserm - InVS; specific action of the National Plan Chlordecone IV.

Read the detailed description

The French West Indies are permanently polluted by chlordecone. It is an organochlorine insecticide used from 1973 to 1993 in Guadeloupe and Martinique to control banana root borers. Its physico-chemical properties give it great stability and are at the origin of its persistence in the environment. Soil, flora and wildlife pollution from chlordecone in the Caribbean was first documented shortly after its introduction in 1973. However, it was not until 1999 that this pollution was extended to waters intended for human consumption and to various local, vegetable and animal, land and aquatic foodstuffs. The population is also affected, as confirmed by impregnation studies, with exposure nowadays occurring mainly through the consumption of contaminated food. The contamination of the French West Indies populations by this insecticide raises many questions about its possible health consequences. In order to assess the effects of chlordecone exposure on child development in Guadeloupian children, a longitudinal and prospective study, the Timoun mother-child cohort, was initiated. Between 2004 and 2007, women in the second trimester of pregnancy who planned to give birth in the public hospitals of Grande-Terre and Basse-Terre (accounting for 70% of all deliveries in Guadeloupe) were invited to participate in the study. Children born to these included women have been enrolled to several follow-ups during the last years (3, 7, 18 months and 7 years of age).

02

Conditions studied

  • Prenatal Exposure
  • Postnatal Exposure

Keywords

  • Prenatal Exposure
  • Postnatal Exposure
  • Chlordecone
  • Persistent Organic Pollutants
  • Endocrine disruptors
  • Puberty
  • Development
  • Guadeloupe
  • French West Indies
03

In context

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 50 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Be born to a mother whose pregnancy was included in the Timoun cohort (2004 - 2007)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be born to a mother whose pregnancy was included in the Timoun cohort (2004 - 2007) and whose parents agreed to be contacted later.
  • Residing in Guadeloupe at the peripubertal age
  • Affiliation to a social security scheme
  • Agreement to participate in the study and signed by the minor
  • Study participation agreement and informed consent signed by the parents

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the research
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • peripubertal children

    Children born from a mother whose pregnancy was included in the Timoun cohort (2004 -2007).

    Other: Clinical examination

Interventions

  • OtherClinical examination

    For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.

    Also known as: Blood collection,, cognitive tests

06

What researchers measure

Primary outcomes

  1. Scores from cognitive development tests estimating verbal comprehension verbal comprehension, perceptual reasoning and working memory

    : Cognitive tests (25 min for the 3 Wechsler Intelligence Scale for Children V subscales). The Wechsler Intelligence Scale for Children-V is the most scientifically valid intelligence test for children and adolescents. It can be used to determine a child's or teenager's intelligence quotient (IQ), to obtain their complete cognitive profile and the level of the 5 main components of cognitive intelligence

    Time frame: At the start of the study (inclusion visit)

Secondary outcomes

  1. Age at onset of pubertal development (onset of accelerated growth acceleration of growth rate, modeled on growth curves)

    Collect of the age at which children and adolescents begin to develop adult physical characteristics, such as breasts or pubic hair, and become able to procreate.

    Time frame: At the start of the study (inclusion visit).

Other outcomes

  1. Age at established puberty (period for girls, molting for boys)

    Collect of the age at which girls had their period and boys molted

    Time frame: At the start of the study (inclusion visit) or through study completion, an average of two years, for girls who had their period and boys molted.

  2. Plasma concentrations of steroid hormones

    Blood collection for hormonal and organochlorine pollutants dosage.

    Time frame: At the start of the study (inclusion visit).

  3. Blood pressure

    Seated resting blood pressure will be measured using an automatic tensiometer an automatic blood pressure monitor, with two measurements separated by 15 to 30 minutes.

    Time frame: At the start of the study (inclusion visit).

  4. heart rate

    heart ratewill be measured using an automatic tensiometer an automatic blood pressure monitor, with two measurements separated by 15 to 30 minutes.

    Time frame: At the start of the study (inclusion visit).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Oct 22, 2024
StartActual
Dec 19, 2022
Primary completionEst.
Dec 19, 2026
CompletionEst.
Dec 19, 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06653660
Lead sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Dec 19, 2022
Primary completion
Dec 19, 2026 (estimated)
Completion
Dec 19, 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Valérie HAMONY-SOTER
Contact
valerie.soter@chu-guadeloupe.fr
+590 590 93 46 77
Eunice NUBRET
Contact
eunice.nubret@chu-guadeloupe.fr
+590 590 93 46 86
Gulen AYHAN
principal investigator · CHU of Guadeloupe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion